Moneycontrol PRO
Loans
Loans
HomeNewsBusinessEarningsBuy Thyrocare Technologies; target of Rs 825: ICICI Securities

Buy Thyrocare Technologies; target of Rs 825: ICICI Securities

ICICI Securities is bullish on Thyrocare Technologies has recommended buy rating on the stock with a target price of Rs 825 in its research report dated July 24, 2024.

July 25, 2024 / 20:52 IST
Buy

Buy

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

ICICI Securitie's research report on Thyrocare Technologies

Pathology revenue was up 16.4% YoY (-0.1% QoQ) to INR 1.4bn. Franchise business grew 11% YoY. Restructuring of franchise business is yielding results. Improvement of mix of big franchisee to small franchisee (added 600 large franchise YoY) is driving growth and it is likely to drive 10-15% growth in FY25E. Partnership business grew 29% YoY, barring sales from API holdings (parent) and B2G business, growth stood at 41% YoY. Normalised margin for pathology segment stood at 31.4%, down 140bps YoY (+560 bps QoQ); radiology sales grew 15.7% YoY to INR 130mn while margins stood at 10.0% down 250bps YoY (+100bps QoQ). In the near term, partnership business may continue to grow faster than franchise business. Bundled wellness package ‘Jaanch’ grew 25% YoY. The company is also introducing new bundled test package with high value and specialised tests. In Q1FY25, it commenced operations in Tanzania, investing INR 40mn (50% stake in JV) so far.

Outlook

Thyrocare Technologies (Thyrocare) has reported a strong 16.4% YoY growth in pathology segment in Q1FY25 in otherwise a seasonally weak quarter. The company had started restructuring of its franchisee business in May’23 which is yielding results as sales contribution from larger franchisee is growing at a faster pace (added 600 franchises in past 1 year) while partnership business (excluding API & B2G) grew 41% YoY in Q1. The newly launched bundled test package ‘Jaanch’ grew at 25% YoY. EBITDA margin expanded 140bps to 27.2% mainly driven by operating leverage and lower ESOP cost. Management expects EBITDA margin in 27-30% range in FY25. We raise FY25/26E EBITDA by 5% each and earnings by 11-12% to factor better margins. Maintain BUY with DCF-based revised TP of INR 825.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

ICICI_THYROCARE TECH

Broker Research
first published: Jul 25, 2024 08:52 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347